Our results suggest that AME:AVE (3:1) treatment modulates the insulin signaling pathway and suppresses the expression of adipogenesis and lipogenesis-related proteins, thereby resulting in anti-obesity effects. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.